神経線維腫症II型治療の世界市場（～2026年）

• 英文タイトル：Global Neurofibromatoses Type II Therapecutics Market Insights and Forecast to 2026

• レポートコード：MRC2-11QY08113 • 出版社/出版日：QYResearch / 2020年11月20日 ※2024年版があります。お問い合わせください。 • レポート形態：英文、PDF、119ページ • 納品方法：Eメール（納期：2~3日） • 産業分類：医療、製薬

• 販売価格（消費税別）

Single User	￥585,000 (USD3,900)	▷ お問い合わせ
Multi User	￥877,500 (USD5,850)	▷ お問い合わせ
Enterprise License	￥1,170,000 (USD7,800)	▷ お問い合わせ

• ご注文方法：お問い合わせフォーム記入又はEメールでご連絡ください。
• お支払方法：銀行振込（納品後、ご請求書送付）

---

レポート概要

---

当調査資料は神経線維腫症II型治療のグローバル市場について調査・分析したレポートです。種類別（AR-42、FRAX-597、塩酸イコチニブ、LB-201、LB-205、その他）市場規模、用途別（クリニック、病院、在宅ケア）市場規模、地域別（北米、米国、カナダ、ヨーロッパ、ドイツ、フランス、イギリス、イタリア、ロシア、アジア、日本、中国、韓国、インド、オーストラリア、台湾、中南米、メキシコ、ブラジル、アルゼンチン、中東・アフリカ、トルコ、サウジアラビア、UAE等）市場規模データ、主な企業情報と企業別市場シェア等が収録されています。 ・調査範囲 ・エグゼクティブサマリー ・企業別神経線維腫症II型治療の競争状況、市場シェア ・世界の神経線維腫症II型治療市場：種類別市場規模 2015年-2020年（AR-42、FRAX-597、塩酸イコチニブ、LB-201、LB-205、その他） ・世界の神経線維腫症II型治療市場：種類別市場規模予測 2021年-2026年（AR-42、FRAX-597、塩酸イコチニブ、LB-201、LB-205、その他） ・世界の神経線維腫症II型治療市場：用途別市場規模 2015年-2020年（クリニック、病院、在宅ケア） ・世界の神経線維腫症II型治療市場：用途別市場規模予測 2021年-2026年（クリニック、病院、在宅ケア） ・北米の神経線維腫症II型治療市場分析：米国、カナダ ・ヨーロッパの神経線維腫症II型治療市場分析：ドイツ、フランス、イギリス、イタリア、ロシア等 ・アジアの神経線維腫症II型治療市場分析：日本、中国、韓国、インド、オーストラリア、台湾等 ・中南米の神経線維腫症II型治療市場分析：メキシコ、ブラジル、アルゼンチン等 ・中東・アフリカの神経線維腫症II型治療市場分析：トルコ、サウジアラビア、UAE等 ・企業情報（企業概要、製品概要、販売量、企業動向） - 掲載企業（変更可能性あり）：Arno Therapeutics Inc、AstraZeneca Plc、Beta Pharma Inc、Lixte Biotechnology Holdings Inc、Plex Pharmaceuticals Inc、Recursion Pharmaceuticals Inc ・地域別市場規模予測（2021年-2026年）：北米市場、ヨーロッパ市場、アジア市場、中南米市場、中東・アフリカ市場 ・市場機会、課題、リスク、環境分析 ・バリューチェーン、販売チャネル分析 ・調査の結論

Market Analysis and Insights: Global Neurofibromatoses Type II Therapecutics Market
The global Neurofibromatoses Type II Therapecutics market size is projected to reach US$ XX million by 2026, from US$ XX million in 2020, at a CAGR of XX%% during 2021-2026.

Global Neurofibromatoses Type II Therapecutics Scope and Market Size
Neurofibromatoses Type II Therapecutics market is segmented by Type, and by Application. Players, stakeholders, and other participants in the global Neurofibromatoses Type II Therapecutics market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on sales, revenue and forecast by Type and by Application for the period 2015-2026.

Segment by Type, the Neurofibromatoses Type II Therapecutics market is segmented into
AR-42
FRAX-597
Icotinib Hydrochloride
LB-201
LB-205
Others

Segment by Application, the Neurofibromatoses Type II Therapecutics market is segmented into
Clinic
Hospital
Home Care

Regional and Country-level Analysis
The Neurofibromatoses Type II Therapecutics market is analysed and market size information is provided by regions (countries).
The key regions covered in the Neurofibromatoses Type II Therapecutics market report are North America, Europe, Asia Pacific, Latin America, Middle East and Africa. It also covers key regions (countries), viz, U.S., Canada, Germany, France, U.K., Italy, Russia, China, Japan, South Korea, India, Australia, Taiwan, Indonesia, Thailand, Malaysia, Philippines, Vietnam, Mexico, Brazil, Turkey, Saudi Arabia, U.A.E, etc.
The report includes country-wise and region-wise market size for the period 2015-2026. It also includes market size and forecast by Type, and by Application segment in terms of sales and revenue for the period 2015-2026.
Competitive Landscape and Neurofibromatoses Type II Therapecutics Market Share Analysis
Neurofibromatoses Type II Therapecutics market competitive landscape provides details and data information by players. The report offers comprehensive analysis and accurate statistics on revenue by the player for the period 2015-2020. It also offers detailed analysis supported by reliable statistics on revenue (global and regional level) by players for the period 2015-2020. Details included are company description, major business, company total revenue and the sales, revenue generated in Neurofibromatoses Type II Therapecutics business, the date to enter into the Neurofibromatoses Type II Therapecutics market, Neurofibromatoses Type II Therapecutics product introduction, recent developments, etc.

The major vendors covered:
Arno Therapeutics Inc
AstraZeneca Plc
Beta Pharma Inc
Lixte Biotechnology Holdings Inc
Plex Pharmaceuticals Inc
Recursion Pharmaceuticals Inc
…

レポート目次

---

1 Study Coverage
1.1 Neurofibromatoses Type II Therapecutics Product Introduction
1.2 Market Segments
1.3 Key Neurofibromatoses Type II Therapecutics Manufacturers Covered: Ranking by Revenue
1.4 Market by Type
1.4.1 Global Neurofibromatoses Type II Therapecutics Market Size Growth Rate by Type
1.4.2 AR-42
1.4.3 FRAX-597
1.4.4 Icotinib Hydrochloride
1.4.5 LB-201
1.4.6 LB-205
1.4.7 Others
1.5 Market by Application
1.5.1 Global Neurofibromatoses Type II Therapecutics Market Size Growth Rate by Application
1.5.2 Clinic
1.5.3 Hospital
1.5.4 Home Care
1.6 Study Objectives
1.7 Years Considered

2 Executive Summary
2.1 Global Neurofibromatoses Type II Therapecutics Market Size, Estimates and Forecasts
2.1.1 Global Neurofibromatoses Type II Therapecutics Revenue 2015-2026
2.1.2 Global Neurofibromatoses Type II Therapecutics Sales 2015-2026
2.2 Global Neurofibromatoses Type II Therapecutics, Market Size by Producing Regions: 2015 VS 2020 VS 2026
2.2.1 Global Neurofibromatoses Type II Therapecutics Retrospective Market Scenario in Sales by Region: 2015-2020
2.2.2 Global Neurofibromatoses Type II Therapecutics Retrospective Market Scenario in Revenue by Region: 2015-2020

3 Global Neurofibromatoses Type II Therapecutics Competitor Landscape by Players
3.1 Neurofibromatoses Type II Therapecutics Sales by Manufacturers
3.1.1 Neurofibromatoses Type II Therapecutics Sales by Manufacturers (2015-2020)
3.1.2 Neurofibromatoses Type II Therapecutics Sales Market Share by Manufacturers (2015-2020)
3.2 Neurofibromatoses Type II Therapecutics Revenue by Manufacturers
3.2.1 Neurofibromatoses Type II Therapecutics Revenue by Manufacturers (2015-2020)
3.2.2 Neurofibromatoses Type II Therapecutics Revenue Share by Manufacturers (2015-2020)
3.2.3 Global Neurofibromatoses Type II Therapecutics Market Concentration Ratio (CR5 and HHI) (2015-2020)
3.2.4 Global Top 10 and Top 5 Companies by Neurofibromatoses Type II Therapecutics Revenue in 2019
3.2.5 Global Neurofibromatoses Type II Therapecutics Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
3.3 Neurofibromatoses Type II Therapecutics Price by Manufacturers
3.4 Neurofibromatoses Type II Therapecutics Manufacturing Base Distribution, Product Types
3.4.1 Neurofibromatoses Type II Therapecutics Manufacturers Manufacturing Base Distribution, Headquarters
3.4.2 Manufacturers Neurofibromatoses Type II Therapecutics Product Type
3.4.3 Date of International Manufacturers Enter into Neurofibromatoses Type II Therapecutics Market
3.5 Manufacturers Mergers & Acquisitions, Expansion Plans

4 Market Size by Type (2015-2026)
4.1 Global Neurofibromatoses Type II Therapecutics Market Size by Type (2015-2020)
4.1.1 Global Neurofibromatoses Type II Therapecutics Sales by Type (2015-2020)
4.1.2 Global Neurofibromatoses Type II Therapecutics Revenue by Type (2015-2020)
4.1.3 Neurofibromatoses Type II Therapecutics Average Selling Price (ASP) by Type (2015-2026)
4.2 Global Neurofibromatoses Type II Therapecutics Market Size Forecast by Type (2021-2026)
4.2.1 Global Neurofibromatoses Type II Therapecutics Sales Forecast by Type (2021-2026)
4.2.2 Global Neurofibromatoses Type II Therapecutics Revenue Forecast by Type (2021-2026)
4.2.3 Neurofibromatoses Type II Therapecutics Average Selling Price (ASP) Forecast by Type (2021-2026)
4.3 Global Neurofibromatoses Type II Therapecutics Market Share by Price Tier (2015-2020): Low-End, Mid-Range and High-End

5 Market Size by Application (2015-2026)
5.1 Global Neurofibromatoses Type II Therapecutics Market Size by Application (2015-2020)
5.1.1 Global Neurofibromatoses Type II Therapecutics Sales by Application (2015-2020)
5.1.2 Global Neurofibromatoses Type II Therapecutics Revenue by Application (2015-2020)
5.1.3 Neurofibromatoses Type II Therapecutics Price by Application (2015-2020)
5.2 Neurofibromatoses Type II Therapecutics Market Size Forecast by Application (2021-2026)
5.2.1 Global Neurofibromatoses Type II Therapecutics Sales Forecast by Application (2021-2026)
5.2.2 Global Neurofibromatoses Type II Therapecutics Revenue Forecast by Application (2021-2026)
5.2.3 Global Neurofibromatoses Type II Therapecutics Price Forecast by Application (2021-2026)

6 North America
6.1 North America Neurofibromatoses Type II Therapecutics by Country
6.1.1 North America Neurofibromatoses Type II Therapecutics Sales by Country
6.1.2 North America Neurofibromatoses Type II Therapecutics Revenue by Country
6.1.3 U.S.
6.1.4 Canada
6.2 North America Neurofibromatoses Type II Therapecutics Market Facts & Figures by Type
6.3 North America Neurofibromatoses Type II Therapecutics Market Facts & Figures by Application

7 Europe
7.1 Europe Neurofibromatoses Type II Therapecutics by Country
7.1.1 Europe Neurofibromatoses Type II Therapecutics Sales by Country
7.1.2 Europe Neurofibromatoses Type II Therapecutics Revenue by Country
7.1.3 Germany
7.1.4 France
7.1.5 U.K.
7.1.6 Italy
7.1.7 Russia
7.2 Europe Neurofibromatoses Type II Therapecutics Market Facts & Figures by Type
7.3 Europe Neurofibromatoses Type II Therapecutics Market Facts & Figures by Application

8 Asia Pacific
8.1 Asia Pacific Neurofibromatoses Type II Therapecutics by Region
8.1.1 Asia Pacific Neurofibromatoses Type II Therapecutics Sales by Region
8.1.2 Asia Pacific Neurofibromatoses Type II Therapecutics Revenue by Region
8.1.3 China
8.1.4 Japan
8.1.5 South Korea
8.1.6 India
8.1.7 Australia
8.1.8 Taiwan
8.1.9 Indonesia
8.1.10 Thailand
8.1.11 Malaysia
8.1.12 Philippines
8.1.13 Vietnam
8.2 Asia Pacific Neurofibromatoses Type II Therapecutics Market Facts & Figures by Type
8.3 Asia Pacific Neurofibromatoses Type II Therapecutics Market Facts & Figures by Application

9 Latin America
9.1 Latin America Neurofibromatoses Type II Therapecutics by Country
9.1.1 Latin America Neurofibromatoses Type II Therapecutics Sales by Country
9.1.2 Latin America Neurofibromatoses Type II Therapecutics Revenue by Country
9.1.3 Mexico
9.1.4 Brazil
9.1.5 Argentina
9.2 Central & South America Neurofibromatoses Type II Therapecutics Market Facts & Figures by Type
9.3 Central & South America Neurofibromatoses Type II Therapecutics Market Facts & Figures by Application

10 Middle East and Africa
10.1 Middle East and Africa Neurofibromatoses Type II Therapecutics by Country
10.1.1 Middle East and Africa Neurofibromatoses Type II Therapecutics Sales by Country
10.1.2 Middle East and Africa Neurofibromatoses Type II Therapecutics Revenue by Country
10.1.3 Turkey
10.1.4 Saudi Arabia
10.1.5 U.A.E
10.2 Middle East and Africa Neurofibromatoses Type II Therapecutics Market Facts & Figures by Type
10.3 Middle East and Africa Neurofibromatoses Type II Therapecutics Market Facts & Figures by Application

11 Company Profiles
11.1 Arno Therapeutics Inc
11.1.1 Arno Therapeutics Inc Corporation Information
11.1.2 Arno Therapeutics Inc Description and Business Overview
11.1.3 Arno Therapeutics Inc Sales, Revenue and Gross Margin (2015-2020)
11.1.4 Arno Therapeutics Inc Neurofibromatoses Type II Therapecutics Products Offered
11.1.5 Arno Therapeutics Inc Related Developments
11.2 AstraZeneca Plc
11.2.1 AstraZeneca Plc Corporation Information
11.2.2 AstraZeneca Plc Description and Business Overview
11.2.3 AstraZeneca Plc Sales, Revenue and Gross Margin (2015-2020)
11.2.4 AstraZeneca Plc Neurofibromatoses Type II Therapecutics Products Offered
11.2.5 AstraZeneca Plc Related Developments
11.3 Beta Pharma Inc
11.3.1 Beta Pharma Inc Corporation Information
11.3.2 Beta Pharma Inc Description and Business Overview
11.3.3 Beta Pharma Inc Sales, Revenue and Gross Margin (2015-2020)
11.3.4 Beta Pharma Inc Neurofibromatoses Type II Therapecutics Products Offered
11.3.5 Beta Pharma Inc Related Developments
11.4 Lixte Biotechnology Holdings Inc
11.4.1 Lixte Biotechnology Holdings Inc Corporation Information
11.4.2 Lixte Biotechnology Holdings Inc Description and Business Overview
11.4.3 Lixte Biotechnology Holdings Inc Sales, Revenue and Gross Margin (2015-2020)
11.4.4 Lixte Biotechnology Holdings Inc Neurofibromatoses Type II Therapecutics Products Offered
11.4.5 Lixte Biotechnology Holdings Inc Related Developments
11.5 Plex Pharmaceuticals Inc
11.5.1 Plex Pharmaceuticals Inc Corporation Information
11.5.2 Plex Pharmaceuticals Inc Description and Business Overview
11.5.3 Plex Pharmaceuticals Inc Sales, Revenue and Gross Margin (2015-2020)
11.5.4 Plex Pharmaceuticals Inc Neurofibromatoses Type II Therapecutics Products Offered
11.5.5 Plex Pharmaceuticals Inc Related Developments
11.6 Recursion Pharmaceuticals Inc
11.6.1 Recursion Pharmaceuticals Inc Corporation Information
11.6.2 Recursion Pharmaceuticals Inc Description and Business Overview
11.6.3 Recursion Pharmaceuticals Inc Sales, Revenue and Gross Margin (2015-2020)
11.6.4 Recursion Pharmaceuticals Inc Neurofibromatoses Type II Therapecutics Products Offered
11.6.5 Recursion Pharmaceuticals Inc Related Developments
11.1 Arno Therapeutics Inc
11.1.1 Arno Therapeutics Inc Corporation Information
11.1.2 Arno Therapeutics Inc Description and Business Overview
11.1.3 Arno Therapeutics Inc Sales, Revenue and Gross Margin (2015-2020)
11.1.4 Arno Therapeutics Inc Neurofibromatoses Type II Therapecutics Products Offered
11.1.5 Arno Therapeutics Inc Related Developments

12 Future Forecast by Regions (Countries) (2021-2026)
12.1 Neurofibromatoses Type II Therapecutics Market Estimates and Projections by Region
12.1.1 Global Neurofibromatoses Type II Therapecutics Sales Forecast by Regions 2021-2026
12.1.2 Global Neurofibromatoses Type II Therapecutics Revenue Forecast by Regions 2021-2026
12.2 North America Neurofibromatoses Type II Therapecutics Market Size Forecast (2021-2026)
12.2.1 North America: Neurofibromatoses Type II Therapecutics Sales Forecast (2021-2026)
12.2.2 North America: Neurofibromatoses Type II Therapecutics Revenue Forecast (2021-2026)
12.2.3 North America: Neurofibromatoses Type II Therapecutics Market Size Forecast by Country (2021-2026)
12.3 Europe Neurofibromatoses Type II Therapecutics Market Size Forecast (2021-2026)
12.3.1 Europe: Neurofibromatoses Type II Therapecutics Sales Forecast (2021-2026)
12.3.2 Europe: Neurofibromatoses Type II Therapecutics Revenue Forecast (2021-2026)
12.3.3 Europe: Neurofibromatoses Type II Therapecutics Market Size Forecast by Country (2021-2026)
12.4 Asia Pacific Neurofibromatoses Type II Therapecutics Market Size Forecast (2021-2026)
12.4.1 Asia Pacific: Neurofibromatoses Type II Therapecutics Sales Forecast (2021-2026)
12.4.2 Asia Pacific: Neurofibromatoses Type II Therapecutics Revenue Forecast (2021-2026)
12.4.3 Asia Pacific: Neurofibromatoses Type II Therapecutics Market Size Forecast by Region (2021-2026)
12.5 Latin America Neurofibromatoses Type II Therapecutics Market Size Forecast (2021-2026)
12.5.1 Latin America: Neurofibromatoses Type II Therapecutics Sales Forecast (2021-2026)
12.5.2 Latin America: Neurofibromatoses Type II Therapecutics Revenue Forecast (2021-2026)
12.5.3 Latin America: Neurofibromatoses Type II Therapecutics Market Size Forecast by Country (2021-2026)
12.6 Middle East and Africa Neurofibromatoses Type II Therapecutics Market Size Forecast (2021-2026)
12.6.1 Middle East and Africa: Neurofibromatoses Type II Therapecutics Sales Forecast (2021-2026)
12.6.2 Middle East and Africa: Neurofibromatoses Type II Therapecutics Revenue Forecast (2021-2026)
12.6.3 Middle East and Africa: Neurofibromatoses Type II Therapecutics Market Size Forecast by Country (2021-2026)

13 Market Opportunities, Challenges, Risks and Influences Factors Analysis
13.1 Market Opportunities and Drivers
13.2 Market Challenges
13.3 Market Risks/Restraints
13.4 Porter’s Five Forces Analysis
13.5 Primary Interviews with Key Neurofibromatoses Type II Therapecutics Players (Opinion Leaders)

14 Value Chain and Sales Channels Analysis
14.1 Value Chain Analysis
14.2 Neurofibromatoses Type II Therapecutics Customers
14.3 Sales Channels Analysis
14.3.1 Sales Channels
14.3.2 Distributors

15 Research Findings and Conclusion

16 Appendix
16.1 Research Methodology
16.1.1 Methodology/Research Approach
16.1.2 Data Source
16.2 Author Details
16.3 Disclaimer

List of Tables
Table 1. Neurofibromatoses Type II Therapecutics Market Segments
Table 2. Ranking of Global Top Neurofibromatoses Type II Therapecutics Manufacturers by Revenue (US$ Million) in 2019
Table 3. Global Neurofibromatoses Type II Therapecutics Market Size Growth Rate by Type 2020-2026 (K Pcs) & (US$ Million)
Table 4. Major Manufacturers of AR-42
Table 5. Major Manufacturers of FRAX-597
Table 6. Major Manufacturers of Icotinib Hydrochloride
Table 7. Major Manufacturers of LB-201
Table 8. Major Manufacturers of LB-205
Table 9. Major Manufacturers of Others
Table 10. Global Neurofibromatoses Type II Therapecutics Market Size Growth Rate by Application 2020-2026 (K Pcs)
Table 11. Global Neurofibromatoses Type II Therapecutics Market Size by Region (K Pcs) & (US$ Million): 2020 VS 2026
Table 12. Global Neurofibromatoses Type II Therapecutics Sales by Regions 2015-2020 (K Pcs)
Table 13. Global Neurofibromatoses Type II Therapecutics Sales Market Share by Regions (2015-2020)
Table 14. Global Neurofibromatoses Type II Therapecutics Revenue by Regions 2015-2020 (US$ Million)
Table 15. Global Neurofibromatoses Type II Therapecutics Sales by Manufacturers (2015-2020) (K Pcs)
Table 16. Global Neurofibromatoses Type II Therapecutics Sales Share by Manufacturers (2015-2020)
Table 17. Global Neurofibromatoses Type II Therapecutics Manufacturers Market Concentration Ratio (CR5 and HHI) (2015-2020)
Table 18. Global Neurofibromatoses Type II Therapecutics by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Neurofibromatoses Type II Therapecutics as of 2019)
Table 19. Neurofibromatoses Type II Therapecutics Revenue by Manufacturers (2015-2020) (US$ Million)
Table 20. Neurofibromatoses Type II Therapecutics Revenue Share by Manufacturers (2015-2020)
Table 21. Key Manufacturers Neurofibromatoses Type II Therapecutics Price (2015-2020) (USD/Pcs)
Table 22. Neurofibromatoses Type II Therapecutics Manufacturers Manufacturing Base Distribution and Headquarters
Table 23. Manufacturers Neurofibromatoses Type II Therapecutics Product Type
Table 24. Date of International Manufacturers Enter into Neurofibromatoses Type II Therapecutics Market
Table 25. Manufacturers Mergers & Acquisitions, Expansion Plans
Table 26. Global Neurofibromatoses Type II Therapecutics Sales by Type (2015-2020) (K Pcs)
Table 27. Global Neurofibromatoses Type II Therapecutics Sales Share by Type (2015-2020)
Table 28. Global Neurofibromatoses Type II Therapecutics Revenue by Type (2015-2020) (US$ Million)
Table 29. Global Neurofibromatoses Type II Therapecutics Revenue Share by Type (2015-2020)
Table 30. Neurofibromatoses Type II Therapecutics Average Selling Price (ASP) by Type 2015-2020 (USD/Pcs)
Table 31. Global Neurofibromatoses Type II Therapecutics Sales by Application (2015-2020) (K Pcs)
Table 32. Global Neurofibromatoses Type II Therapecutics Sales Share by Application (2015-2020)
Table 33. North America Neurofibromatoses Type II Therapecutics Sales by Country (2015-2020) (K Pcs)
Table 34. North America Neurofibromatoses Type II Therapecutics Sales Market Share by Country (2015-2020)
Table 35. North America Neurofibromatoses Type II Therapecutics Revenue by Country (2015-2020) (US$ Million)
Table 36. North America Neurofibromatoses Type II Therapecutics Revenue Market Share by Country (2015-2020)
Table 37. North America Neurofibromatoses Type II Therapecutics Sales by Type (2015-2020) (K Pcs)
Table 38. North America Neurofibromatoses Type II Therapecutics Sales Market Share by Type (2015-2020)
Table 39. North America Neurofibromatoses Type II Therapecutics Sales by Application (2015-2020) (K Pcs)
Table 40. North America Neurofibromatoses Type II Therapecutics Sales Market Share by Application (2015-2020)
Table 41. Europe Neurofibromatoses Type II Therapecutics Sales by Country (2015-2020) (K Pcs)
Table 42. Europe Neurofibromatoses Type II Therapecutics Sales Market Share by Country (2015-2020)
Table 43. Europe Neurofibromatoses Type II Therapecutics Revenue by Country (2015-2020) (US$ Million)
Table 44. Europe Neurofibromatoses Type II Therapecutics Revenue Market Share by Country (2015-2020)
Table 45. Europe Neurofibromatoses Type II Therapecutics Sales by Type (2015-2020) (K Pcs)
Table 46. Europe Neurofibromatoses Type II Therapecutics Sales Market Share by Type (2015-2020)
Table 47. Europe Neurofibromatoses Type II Therapecutics Sales by Application (2015-2020) (K Pcs)
Table 48. Europe Neurofibromatoses Type II Therapecutics Sales Market Share by Application (2015-2020)
Table 49. Asia Pacific Neurofibromatoses Type II Therapecutics Sales by Region (2015-2020) (K Pcs)
Table 50. Asia Pacific Neurofibromatoses Type II Therapecutics Sales Market Share by Region (2015-2020)
Table 51. Asia Pacific Neurofibromatoses Type II Therapecutics Revenue by Region (2015-2020) (US$ Million)
Table 52. Asia Pacific Neurofibromatoses Type II Therapecutics Revenue Market Share by Region (2015-2020)
Table 53. Asia Pacific Neurofibromatoses Type II Therapecutics Sales by Type (2015-2020) (K Pcs)
Table 54. Asia Pacific Neurofibromatoses Type II Therapecutics Sales Market Share by Type (2015-2020)
Table 55. Asia Pacific Neurofibromatoses Type II Therapecutics Sales by Application (2015-2020) (K Pcs)
Table 56. Asia Pacific Neurofibromatoses Type II Therapecutics Sales Market Share by Application (2015-2020)
Table 57. Latin America Neurofibromatoses Type II Therapecutics Sales by Country (2015-2020) (K Pcs)
Table 58. Latin America Neurofibromatoses Type II Therapecutics Sales Market Share by Country (2015-2020)
Table 59. Latin Americaa Neurofibromatoses Type II Therapecutics Revenue by Country (2015-2020) (US$ Million)
Table 60. Latin America Neurofibromatoses Type II Therapecutics Revenue Market Share by Country (2015-2020)
Table 61. Latin America Neurofibromatoses Type II Therapecutics Sales by Type (2015-2020) (K Pcs)
Table 62. Latin America Neurofibromatoses Type II Therapecutics Sales Market Share by Type (2015-2020)
Table 63. Latin America Neurofibromatoses Type II Therapecutics Sales by Application (2015-2020) (K Pcs)
Table 64. Latin America Neurofibromatoses Type II Therapecutics Sales Market Share by Application (2015-2020)
Table 65. Middle East and Africa Neurofibromatoses Type II Therapecutics Sales by Country (2015-2020) (K Pcs)
Table 66. Middle East and Africa Neurofibromatoses Type II Therapecutics Sales Market Share by Country (2015-2020)
Table 67. Middle East and Africa Neurofibromatoses Type II Therapecutics Revenue by Country (2015-2020) (US$ Million)
Table 68. Middle East and Africa Neurofibromatoses Type II Therapecutics Revenue Market Share by Country (2015-2020)
Table 69. Middle East and Africa Neurofibromatoses Type II Therapecutics Sales by Type (2015-2020) (K Pcs)
Table 70. Middle East and Africa Neurofibromatoses Type II Therapecutics Sales Market Share by Type (2015-2020)
Table 71. Middle East and Africa Neurofibromatoses Type II Therapecutics Sales by Application (2015-2020) (K Pcs)
Table 72. Middle East and Africa Neurofibromatoses Type II Therapecutics Sales Market Share by Application (2015-2020)
Table 73. Arno Therapeutics Inc Corporation Information
Table 74. Arno Therapeutics Inc Description and Major Businesses
Table 75. Arno Therapeutics Inc Neurofibromatoses Type II Therapecutics Production (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 76. Arno Therapeutics Inc Product
Table 77. Arno Therapeutics Inc Recent Development
Table 78. AstraZeneca Plc Corporation Information
Table 79. AstraZeneca Plc Description and Major Businesses
Table 80. AstraZeneca Plc Neurofibromatoses Type II Therapecutics Production (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 81. AstraZeneca Plc Product
Table 82. AstraZeneca Plc Recent Development
Table 83. Beta Pharma Inc Corporation Information
Table 84. Beta Pharma Inc Description and Major Businesses
Table 85. Beta Pharma Inc Neurofibromatoses Type II Therapecutics Production (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 86. Beta Pharma Inc Product
Table 87. Beta Pharma Inc Recent Development
Table 88. Lixte Biotechnology Holdings Inc Corporation Information
Table 89. Lixte Biotechnology Holdings Inc Description and Major Businesses
Table 90. Lixte Biotechnology Holdings Inc Neurofibromatoses Type II Therapecutics Production (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 91. Lixte Biotechnology Holdings Inc Product
Table 92. Lixte Biotechnology Holdings Inc Recent Development
Table 93. Plex Pharmaceuticals Inc Corporation Information
Table 94. Plex Pharmaceuticals Inc Description and Major Businesses
Table 95. Plex Pharmaceuticals Inc Neurofibromatoses Type II Therapecutics Production (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 96. Plex Pharmaceuticals Inc Product
Table 97. Plex Pharmaceuticals Inc Recent Development
Table 98. Recursion Pharmaceuticals Inc Corporation Information
Table 99. Recursion Pharmaceuticals Inc Description and Major Businesses
Table 100. Recursion Pharmaceuticals Inc Neurofibromatoses Type II Therapecutics Production (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 101. Recursion Pharmaceuticals Inc Product
Table 102. Recursion Pharmaceuticals Inc Recent Development
Table 103. Global Neurofibromatoses Type II Therapecutics Sales Forecast by Regions (2021-2026) (K Pcs)
Table 104. Global Neurofibromatoses Type II Therapecutics Sales Market Share Forecast by Regions (2021-2026)
Table 105. Global Neurofibromatoses Type II Therapecutics Revenue Forecast by Regions (2021-2026) (US$ Million)
Table 106. Global Neurofibromatoses Type II Therapecutics Revenue Market Share Forecast by Regions (2021-2026)
Table 107. North America: Neurofibromatoses Type II Therapecutics Sales Forecast by Country (2021-2026) (K Pcs)
Table 108. North America: Neurofibromatoses Type II Therapecutics Revenue Forecast by Country (2021-2026) (US$ Million)
Table 109. Europe: Neurofibromatoses Type II Therapecutics Sales Forecast by Country (2021-2026) (K Pcs)
Table 110. Europe: Neurofibromatoses Type II Therapecutics Revenue Forecast by Country (2021-2026) (US$ Million)
Table 111. Asia Pacific: Neurofibromatoses Type II Therapecutics Sales Forecast by Region (2021-2026) (K Pcs)
Table 112. Asia Pacific: Neurofibromatoses Type II Therapecutics Revenue Forecast by Region (2021-2026) (US$ Million)
Table 113. Latin America: Neurofibromatoses Type II Therapecutics Sales Forecast by Country (2021-2026) (K Pcs)
Table 114. Latin America: Neurofibromatoses Type II Therapecutics Revenue Forecast by Country (2021-2026) (US$ Million)
Table 115. Middle East and Africa: Neurofibromatoses Type II Therapecutics Sales Forecast by Country (2021-2026) (K Pcs)
Table 116. Middle East and Africa: Neurofibromatoses Type II Therapecutics Revenue Forecast by Country (2021-2026) (US$ Million)
Table 117. Key Opportunities and Drivers: Impact Analysis (2021-2026)
Table 118. Key Challenges
Table 119. Market Risks
Table 120. Main Points Interviewed from Key Neurofibromatoses Type II Therapecutics Players
Table 121. Neurofibromatoses Type II Therapecutics Customers List
Table 122. Neurofibromatoses Type II Therapecutics Distributors List
Table 123. Research Programs/Design for This Report
Table 124. Key Data Information from Secondary Sources
Table 125. Key Data Information from Primary Sources
List of Figures
Figure 1. Neurofibromatoses Type II Therapecutics Product Picture
Figure 2. Global Neurofibromatoses Type II Therapecutics Sales Market Share by Type in 2020 & 2026
Figure 3. AR-42 Product Picture
Figure 4. FRAX-597 Product Picture
Figure 5. Icotinib Hydrochloride Product Picture
Figure 6. LB-201 Product Picture
Figure 7. LB-205 Product Picture
Figure 8. Others Product Picture
Figure 9. Global Neurofibromatoses Type II Therapecutics Sales Market Share by Application in 2020 & 2026
Figure 10. Clinic
Figure 11. Hospital
Figure 12. Home Care
Figure 13. Neurofibromatoses Type II Therapecutics Report Years Considered
Figure 14. Global Neurofibromatoses Type II Therapecutics Market Size 2015-2026 (US$ Million)
Figure 15. Global Neurofibromatoses Type II Therapecutics Sales 2015-2026 (K Pcs)
Figure 16. Global Neurofibromatoses Type II Therapecutics Market Size Market Share by Region: 2020 Versus 2026
Figure 17. Global Neurofibromatoses Type II Therapecutics Sales Market Share by Region (2015-2020)
Figure 18. Global Neurofibromatoses Type II Therapecutics Sales Market Share by Region in 2019
Figure 19. Global Neurofibromatoses Type II Therapecutics Revenue Market Share by Region (2015-2020)
Figure 20. Global Neurofibromatoses Type II Therapecutics Revenue Market Share by Region in 2019
Figure 21. Global Neurofibromatoses Type II Therapecutics Sales Share by Manufacturer in 2019
Figure 22. The Top 10 and 5 Players Market Share by Neurofibromatoses Type II Therapecutics Revenue in 2019
Figure 23. Neurofibromatoses Type II Therapecutics Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2015 VS 2019
Figure 24. Global Neurofibromatoses Type II Therapecutics Sales Market Share by Type (2015-2020)
Figure 25. Global Neurofibromatoses Type II Therapecutics Sales Market Share by Type in 2019
Figure 26. Global Neurofibromatoses Type II Therapecutics Revenue Market Share by Type (2015-2020)
Figure 27. Global Neurofibromatoses Type II Therapecutics Revenue Market Share by Type in 2019
Figure 28. Global Neurofibromatoses Type II Therapecutics Market Share by Price Range (2015-2020)
Figure 29. Global Neurofibromatoses Type II Therapecutics Sales Market Share by Application (2015-2020)
Figure 30. Global Neurofibromatoses Type II Therapecutics Sales Market Share by Application in 2019
Figure 31. Global Neurofibromatoses Type II Therapecutics Revenue Market Share by Application (2015-2020)
Figure 32. Global Neurofibromatoses Type II Therapecutics Revenue Market Share by Application in 2019
Figure 33. North America Neurofibromatoses Type II Therapecutics Sales Growth Rate 2015-2020 (K Pcs)
Figure 34. North America Neurofibromatoses Type II Therapecutics Revenue Growth Rate 2015-2020 (US$ Million)
Figure 35. North America Neurofibromatoses Type II Therapecutics Sales Market Share by Country in 2019
Figure 36. North America Neurofibromatoses Type II Therapecutics Revenue Market Share by Country in 2019
Figure 37. U.S. Neurofibromatoses Type II Therapecutics Sales Growth Rate (2015-2020) (K Pcs)
Figure 38. U.S. Neurofibromatoses Type II Therapecutics Revenue Growth Rate (2015-2020) (US$ Million)
Figure 39. Canada Neurofibromatoses Type II Therapecutics Sales Growth Rate (2015-2020) (K Pcs)
Figure 40. Canada Neurofibromatoses Type II Therapecutics Revenue Growth Rate (2015-2020) (US$ Million)
Figure 41. North America Neurofibromatoses Type II Therapecutics Market Share by Type in 2019
Figure 42. North America Neurofibromatoses Type II Therapecutics Market Share by Application in 2019
Figure 43. Europe Neurofibromatoses Type II Therapecutics Sales Growth Rate 2015-2020 (K Pcs)
Figure 44. Europe Neurofibromatoses Type II Therapecutics Revenue Growth Rate 2015-2020 (US$ Million)
Figure 45. Europe Neurofibromatoses Type II Therapecutics Sales Market Share by Country in 2019
Figure 46. Europe Neurofibromatoses Type II Therapecutics Revenue Market Share by Country in 2019
Figure 47. Germany Neurofibromatoses Type II Therapecutics Sales Growth Rate (2015-2020) (K Pcs)
Figure 48. Germany Neurofibromatoses Type II Therapecutics Revenue Growth Rate (2015-2020) (US$ Million)
Figure 49. France Neurofibromatoses Type II Therapecutics Sales Growth Rate (2015-2020) (K Pcs)
Figure 50. France Neurofibromatoses Type II Therapecutics Revenue Growth Rate (2015-2020) (US$ Million)
Figure 51. U.K. Neurofibromatoses Type II Therapecutics Sales Growth Rate (2015-2020) (K Pcs)
Figure 52. U.K. Neurofibromatoses Type II Therapecutics Revenue Growth Rate (2015-2020) (US$ Million)
Figure 53. Italy Neurofibromatoses Type II Therapecutics Sales Growth Rate (2015-2020) (K Pcs)
Figure 54. Italy Neurofibromatoses Type II Therapecutics Revenue Growth Rate (2015-2020) (US$ Million)
Figure 55. Russia Neurofibromatoses Type II Therapecutics Sales Growth Rate (2015-2020) (K Pcs)
Figure 56. Russia Neurofibromatoses Type II Therapecutics Revenue Growth Rate (2015-2020) (US$ Million)
Figure 57. Europe Neurofibromatoses Type II Therapecutics Market Share by Type in 2019
Figure 58. Europe Neurofibromatoses Type II Therapecutics Market Share by Application in 2019
Figure 59. Asia Pacific Neurofibromatoses Type II Therapecutics Sales Growth Rate 2015-2020 (K Pcs)
Figure 60. Asia Pacific Neurofibromatoses Type II Therapecutics Revenue Growth Rate 2015-2020 (US$ Million)
Figure 61. Asia Pacific Neurofibromatoses Type II Therapecutics Sales Market Share by Region in 2019
Figure 62. Asia Pacific Neurofibromatoses Type II Therapecutics Revenue Market Share by Region in 2019
Figure 63. China Neurofibromatoses Type II Therapecutics Sales Growth Rate (2015-2020) (K Pcs)
Figure 64. China Neurofibromatoses Type II Therapecutics Revenue Growth Rate (2015-2020) (US$ Million)
Figure 65. Japan Neurofibromatoses Type II Therapecutics Sales Growth Rate (2015-2020) (K Pcs)
Figure 66. Japan Neurofibromatoses Type II Therapecutics Revenue Growth Rate (2015-2020) (US$ Million)
Figure 67. South Korea Neurofibromatoses Type II Therapecutics Sales Growth Rate (2015-2020) (K Pcs)
Figure 68. South Korea Neurofibromatoses Type II Therapecutics Revenue Growth Rate (2015-2020) (US$ Million)
Figure 69. India Neurofibromatoses Type II Therapecutics Sales Growth Rate (2015-2020) (K Pcs)
Figure 70. India Neurofibromatoses Type II Therapecutics Revenue Growth Rate (2015-2020) (US$ Million)
Figure 71. Australia Neurofibromatoses Type II Therapecutics Sales Growth Rate (2015-2020) (K Pcs)
Figure 72. Australia Neurofibromatoses Type II Therapecutics Revenue Growth Rate (2015-2020) (US$ Million)
Figure 73. Taiwan Neurofibromatoses Type II Therapecutics Sales Growth Rate (2015-2020) (K Pcs)
Figure 74. Taiwan Neurofibromatoses Type II Therapecutics Revenue Growth Rate (2015-2020) (US$ Million)
Figure 75. Indonesia Neurofibromatoses Type II Therapecutics Sales Growth Rate (2015-2020) (K Pcs)
Figure 76. Indonesia Neurofibromatoses Type II Therapecutics Revenue Growth Rate (2015-2020) (US$ Million)
Figure 77. Thailand Neurofibromatoses Type II Therapecutics Sales Growth Rate (2015-2020) (K Pcs)
Figure 78. Thailand Neurofibromatoses Type II Therapecutics Revenue Growth Rate (2015-2020) (US$ Million)
Figure 79. Malaysia Neurofibromatoses Type II Therapecutics Sales Growth Rate (2015-2020) (K Pcs)
Figure 80. Malaysia Neurofibromatoses Type II Therapecutics Revenue Growth Rate (2015-2020) (US$ Million)
Figure 81. Philippines Neurofibromatoses Type II Therapecutics Sales Growth Rate (2015-2020) (K Pcs)
Figure 82. Philippines Neurofibromatoses Type II Therapecutics Revenue Growth Rate (2015-2020) (US$ Million)
Figure 83. Vietnam Neurofibromatoses Type II Therapecutics Sales Growth Rate (2015-2020) (K Pcs)
Figure 84. Vietnam Neurofibromatoses Type II Therapecutics Revenue Growth Rate (2015-2020) (US$ Million)
Figure 85. Asia Pacific Neurofibromatoses Type II Therapecutics Market Share by Type in 2019
Figure 86. Asia Pacific Neurofibromatoses Type II Therapecutics Market Share by Application in 2019
Figure 87. Latin America Neurofibromatoses Type II Therapecutics Sales Growth Rate 2015-2020 (K Pcs)
Figure 88. Latin America Neurofibromatoses Type II Therapecutics Revenue Growth Rate 2015-2020 (US$ Million)
Figure 89. Latin America Neurofibromatoses Type II Therapecutics Sales Market Share by Country in 2019
Figure 90. Latin America Neurofibromatoses Type II Therapecutics Revenue Market Share by Country in 2019
Figure 91. Mexico Neurofibromatoses Type II Therapecutics Sales Growth Rate (2015-2020) (K Pcs)
Figure 92. Mexico Neurofibromatoses Type II Therapecutics Revenue Growth Rate (2015-2020) (US$ Million)
Figure 93. Brazil Neurofibromatoses Type II Therapecutics Sales Growth Rate (2015-2020) (K Pcs)
Figure 94. Brazil Neurofibromatoses Type II Therapecutics Revenue Growth Rate (2015-2020) (US$ Million)
Figure 95. Argentina Neurofibromatoses Type II Therapecutics Sales Growth Rate (2015-2020) (K Pcs)
Figure 96. Argentina Neurofibromatoses Type II Therapecutics Revenue Growth Rate (2015-2020) (US$ Million)
Figure 97. Latin America Neurofibromatoses Type II Therapecutics Market Share by Type in 2019
Figure 98. Latin America Neurofibromatoses Type II Therapecutics Market Share by Application in 2019
Figure 99. Middle East and Africa Neurofibromatoses Type II Therapecutics Sales Growth Rate 2015-2020 (K Pcs)
Figure 100. Middle East and Africa Neurofibromatoses Type II Therapecutics Revenue Growth Rate 2015-2020 (US$ Million)
Figure 101. Middle East and Africa Neurofibromatoses Type II Therapecutics Sales Market Share by Country in 2019
Figure 102. Middle East and Africa Neurofibromatoses Type II Therapecutics Revenue Market Share by Country in 2019
Figure 103. Turkey Neurofibromatoses Type II Therapecutics Sales Growth Rate (2015-2020) (K Pcs)
Figure 104. Turkey Neurofibromatoses Type II Therapecutics Revenue Growth Rate (2015-2020) (US$ Million)
Figure 105. Saudi Arabia Neurofibromatoses Type II Therapecutics Sales Growth Rate (2015-2020) (K Pcs)
Figure 106. Saudi Arabia Neurofibromatoses Type II Therapecutics Revenue Growth Rate (2015-2020) (US$ Million)
Figure 107. U.A.E Neurofibromatoses Type II Therapecutics Sales Growth Rate (2015-2020) (K Pcs)
Figure 108. U.A.E Neurofibromatoses Type II Therapecutics Revenue Growth Rate (2015-2020) (US$ Million)
Figure 109. Middle East and Africa Neurofibromatoses Type II Therapecutics Market Share by Type in 2019
Figure 110. Middle East and Africa Neurofibromatoses Type II Therapecutics Market Share by Application in 2019
Figure 111. North America Neurofibromatoses Type II Therapecutics Sales Growth Rate Forecast (2021-2026) (K Pcs)
Figure 112. North America Neurofibromatoses Type II Therapecutics Revenue Growth Rate Forecast (2021-2026) (US$ Million)
Figure 113. Europe Neurofibromatoses Type II Therapecutics Sales Growth Rate Forecast (2021-2026) (K Pcs)
Figure 114. Europe Neurofibromatoses Type II Therapecutics Revenue Growth Rate Forecast (2021-2026) (US$ Million)
Figure 115. Asia Pacific Neurofibromatoses Type II Therapecutics Sales Growth Rate Forecast (2021-2026) (K Pcs)
Figure 116. Asia Pacific Neurofibromatoses Type II Therapecutics Revenue Growth Rate Forecast (2021-2026) (US$ Million)
Figure 117. Latin America Neurofibromatoses Type II Therapecutics Sales Growth Rate Forecast (2021-2026) (K Pcs)
Figure 118. Latin America Neurofibromatoses Type II Therapecutics Revenue Growth Rate Forecast (2021-2026) (US$ Million)
Figure 119. Middle East and Africa Neurofibromatoses Type II Therapecutics Sales Growth Rate Forecast (2021-2026) (K Pcs)
Figure 120. Middle East and Africa Neurofibromatoses Type II Therapecutics Revenue Growth Rate Forecast (2021-2026) (US$ Million)
Figure 121. Porter's Five Forces Analysis
Figure 122. Channels of Distribution
Figure 123. Distributors Profiles
Figure 124. Bottom-up and Top-down Approaches for This Report
Figure 125. Data Triangulation
Figure 126. Key Executives Interviewed

---